Tamboboy, Maria Teresa C.
HRN: 15-80-75 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/29/2022
CO-AMOXICLAV 625MG (TAB)
11/29/2022
12/06/2022
PO
625mg
BID X 7 Days
Post Partum; PROM
Waiting Final Action
Indication: Empirical De-escalation Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes